{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T16:13:37Z","timestamp":1779293617224,"version":"3.51.4"},"reference-count":34,"publisher":"Baishideng Publishing Group Inc.","issue":"35","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["WJG"],"published-print":{"date-parts":[[2022,9,21]]},"DOI":"10.3748\/wjg.v28.i35.5129","type":"journal-article","created":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T08:38:21Z","timestamp":1663231101000},"page":"5129-5140","source":"Crossref","is-referenced-by-count":13,"title":["Combination strategies for pharmacologic treatment of non-alcoholic steatohepatitis"],"prefix":"10.3748","volume":"28","author":[{"given":"Jaspreet","family":"Suri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"Borja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph K","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2060","reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1419"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.11.039"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0104-9"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-0165"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2016-2775"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2019-319104"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/b978-0-323-99764-5.00013-5"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2020.100057"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00803-X"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2028395"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(19)30184-0"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.08.004"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2019.12.129"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/s0168-8278(20)30653-x"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2018.07.027"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/s0618-8278(19)30266-x"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.10.023"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)33041-7"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.01.038"},{"key":"B20","unstructured":"Ratziu V, Ladron-De-Guevara L, Safadi R, Poordad F, Fuster F, Flores-Figueroa J, Harrison SA, Arrese M, Fargion S, Ben-Bashat D.   One-year results of the global phase 2b randomized placebo-controlled arrest trial of aramchol, a stearoyl CoA desaturase inhibitor, in patients with NASH. In: Hepatology. WILEY 111 RIVER ST, HOBOKEN 07030-5774, NJ United States, 2018: 1448A-1449A"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29477"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2019.105922"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32517-6"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2019.11.296"},{"key":"B25","doi-asserted-by":"crossref","unstructured":"Sanyal AJ, Ratziu V, Loomba R, Rinella M, Anstee QM, Goodman Z, Bedossa P, Khalili M, Boursier J, Stinton L.   Obeticholic acid treatment in patients with non-alcoholic steatohepatitis: a secondary analysis in the regenerate study across fibrosis stages. In: AISF Annual Meeting 2020, 2020: 46\u20137","DOI":"10.1016\/j.dld.2019.12.043"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31622"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23784"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/s1542-3565(04)00014-x"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29367"},{"key":"B30","doi-asserted-by":"crossref","unstructured":"Noel B, Ratziu V, Harrison S, Rigou G, degallaix nathalie, texier frederic, Brozek J, Daix V, Belanger C, roudot alice, megnien sophie, hum dean, staels bart, Walczak R, sanyal arun.   Combination drug therapy allows synergistic therapeutic dosereduction in NASH: A case study of ELAFIBRANOR (GFT505) and an FXR agonist combination in a model of severe NASH. 2017. [cited 10 January 2022]. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827817304877","DOI":"10.1016\/S0168-8278(17)30487-7"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14209"},{"key":"B32","unstructured":"Lawitz EJ, Neff G, Ruane PJ, Younes Z, Zhang J, Jia C, Chuang J, Huss R, Chung C, Subramanian M.   Fenofibrate mitigates increases in serum triglycerides due to the ACC inhibitor firsocostat in patients with advanced fibrosis due to NASH: a phase 2 randomized trial. In: Hepatology. WILEY 111 RIVER ST, HOBOKEN 07030-5774, NJ United States, 2019: 1489A-1490A"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.06.006"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2019.10.006"}],"container-title":["World Journal of Gastroenterology"],"original-title":[],"link":[{"URL":"https:\/\/www.wjgnet.com\/1007-9327\/full\/v28\/i35\/5129.htm","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T08:38:42Z","timestamp":1663231122000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.wjgnet.com\/1007-9327\/full\/v28\/i35\/5129.htm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,21]]},"references-count":34,"journal-issue":{"issue":"35"},"URL":"https:\/\/doi.org\/10.3748\/wjg.v28.i35.5129","relation":{},"ISSN":["1007-9327"],"issn-type":[{"value":"1007-9327","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9,21]]}}}